DRRX

DURECT Corporation

Last Updated:

Q3 '20

Price

quotes and stock data delayed 15 minutes

Cash

$48.6M

Burn Rate (Qtr)

$9.3M

Company Profile

DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DUR-928, the company's lead drug candidate is in clinical development for the potential treatment of alcoholic hepatitis (AH), COVID-19 patients with acute liver or kidney injury, and nonalcoholic steatohepatitis (NASH).

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

POSIMIR®(bupivacaine extended-release solution)

Post Operative Pain

NDA Acceptance

TBD

DUR-928

Alcoholic Hepatitis (AH)

Phase 2 Initiation

TBD

DUR-928

COVID-19 Associated Acute Liver or Kidney Injury

Phase 2 Topline Data

TBD

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon